• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探讨非小细胞肺癌中三级淋巴样结构成熟的影响:来自 TLS 评分的见解。

Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.

机构信息

Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

出版信息

Front Immunol. 2024 Sep 20;15:1422206. doi: 10.3389/fimmu.2024.1422206. eCollection 2024.

DOI:10.3389/fimmu.2024.1422206
PMID:39376565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457083/
Abstract

Tertiary Lymphoid Structures (TLS) are lymphoid structures commonly associated with improved survival of cancer patients and response to immunotherapies. However, conflicting reports underscore the need to consider TLS heterogeneity and multiple features such as TLS size, composition, and maturation status, when assessing their functional impact. With the aim of gaining insights into TLS biology and evaluating the prognostic impact of TLS maturity in Non-Small Cell Lung Carcinoma (NSCLC), we developed a multiplex immunofluorescent (mIF) panel including T cell (CD3, CD8), B cell (CD20), Follicular Dendritic cell (FDC) (CD21, CD23) and mature dendritic cell (DC-LAMP) markers. We deployed this panel across a cohort of primary tumor resections from NSCLC patients (N=406) and established a mIF image analysis workstream to specifically detect TLS structures and evaluate the density of each cell phenotype. We assessed the prognostic significance of TLS size, number, and composition, to develop a TLS scoring system representative of TLS biology within a tumor. TLS relative area, (total TLS area divided by the total tumor area), was the most prognostic TLS feature (C-index: 0.54, p = 0.04). CD21 positivity was a marker driving the favorable prognostic impact, where CD21 CD23 B cells (C-index: 0.57, p = 0.04) and CD21 CD23 FDC (C-index: 0.58, p = 0.01) were the only prognostic cell phenotypes in TLS. Combining the three most robust prognostic TLS features: TLS relative area, the density of B cells, and FDC CD21 CD23 we generated a TLS scoring system that demonstrated strong prognostic value in NSCLC when considering the effect of age, sex, histology, and smoking status. This TLS Score also demonstrated significant association with Immunoscore, EGFR mutational status and gene expression-based B-cell and TLS signature scores. It was not correlated with PD-L1 status in tumor cells or immune cells. In conclusion, we generated a prognostic TLS Score representative of the TLS heterogeneity and maturity undergoing within NSCLC tissues. This score could be used as a tool to explore how TLS presence and maturity impact the organization of the tumor microenvironment and support the discovery of spatial biomarker surrogates of TLS maturity, that could be used in the clinic.

摘要

三级淋巴结构(TLS)是与癌症患者生存改善和免疫治疗反应相关的淋巴结构。然而,相互矛盾的报告强调,在评估其功能影响时,需要考虑 TLS 的异质性和多个特征,如 TLS 的大小、组成和成熟状态。为了深入了解 TLS 生物学,并评估 TLS 成熟度对非小细胞肺癌(NSCLC)的预后影响,我们开发了一种包含 T 细胞(CD3、CD8)、B 细胞(CD20)、滤泡树突状细胞(FDC)(CD21、CD23)和成熟树突状细胞(DC-LAMP)标志物的多重免疫荧光(mIF)面板。我们将该面板应用于 NSCLC 患者的原发性肿瘤切除标本队列(N=406),并建立了 mIF 图像分析工作流程,专门用于检测 TLS 结构并评估每种细胞表型的密度。我们评估了 TLS 大小、数量和组成的预后意义,以开发代表肿瘤内 TLS 生物学的 TLS 评分系统。TLS 相对面积(TLS 总面积除以肿瘤总面积)是最具预后意义的 TLS 特征(C 指数:0.54,p=0.04)。CD21 阳性是具有有利预后影响的标志物,其中 CD21 CD23 B 细胞(C 指数:0.57,p=0.04)和 CD21 CD23 FDC(C 指数:0.58,p=0.01)是 TLS 中唯一具有预后意义的细胞表型。将三个最稳健的预后 TLS 特征:TLS 相对面积、B 细胞密度和 FDC CD21 CD23 相结合,我们生成了一个 TLS 评分系统,在考虑年龄、性别、组织学和吸烟状态的影响时,该系统在 NSCLC 中具有很强的预后价值。该 TLS 评分还与免疫评分、EGFR 突变状态以及基于基因表达的 B 细胞和 TLS 特征评分显著相关。它与肿瘤细胞或免疫细胞中的 PD-L1 状态不相关。总之,我们生成了一个代表 NSCLC 组织内发生的 TLS 异质性和成熟度的预后 TLS 评分。该评分可作为一种工具,用于探索 TLS 的存在和成熟度如何影响肿瘤微环境的组织,并支持发现 TLS 成熟度的空间生物标志物替代物,这些替代物可用于临床。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/4d4398228f14/fimmu-15-1422206-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/70ae27f0c33f/fimmu-15-1422206-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/4648a450af52/fimmu-15-1422206-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/04233dc59c99/fimmu-15-1422206-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/e72ba0949483/fimmu-15-1422206-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/e94c2ca50995/fimmu-15-1422206-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/4d4398228f14/fimmu-15-1422206-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/70ae27f0c33f/fimmu-15-1422206-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/4648a450af52/fimmu-15-1422206-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/04233dc59c99/fimmu-15-1422206-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/e72ba0949483/fimmu-15-1422206-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/e94c2ca50995/fimmu-15-1422206-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bcc/11457083/4d4398228f14/fimmu-15-1422206-g006.jpg

相似文献

1
Exploring the impact of tertiary lymphoid structures maturity in NSCLC: insights from TLS scoring.探讨非小细胞肺癌中三级淋巴样结构成熟的影响:来自 TLS 评分的见解。
Front Immunol. 2024 Sep 20;15:1422206. doi: 10.3389/fimmu.2024.1422206. eCollection 2024.
2
Density of tertiary lymphoid structures and their correlation with prognosis in non-small cell lung cancer.三级淋巴结构密度及其与非小细胞肺癌预后的相关性。
Front Immunol. 2024 Aug 13;15:1423775. doi: 10.3389/fimmu.2024.1423775. eCollection 2024.
3
Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.生发中心决定肺鳞癌中三级淋巴结构的预后相关性,并被皮质类固醇所抑制。
Cancer Res. 2018 Mar 1;78(5):1308-1320. doi: 10.1158/0008-5472.CAN-17-1987. Epub 2017 Dec 26.
4
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.三级淋巴结构评分:一种有前途的方法,可细化切除的非小细胞肺癌的 TNM 分期。
Br J Cancer. 2021 May;124(10):1680-1689. doi: 10.1038/s41416-021-01307-y. Epub 2021 Mar 15.
5
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.肿瘤相关三级淋巴结构中的树突状细胞提示 Th1 细胞毒性免疫微环境,并赋予浸润 CD8+ T 细胞的阳性预后价值。
Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23.
6
Prognostic and clinicopathological significance of tertiary lymphoid structure in non-small cell lung cancer: a systematic review and meta-analysis.三级淋巴结构在非小细胞肺癌中的预后和临床病理意义:系统评价和荟萃分析。
BMC Cancer. 2024 Jul 8;24(1):815. doi: 10.1186/s12885-024-12587-x.
7
Multi-omics profiling and experimental verification of tertiary lymphoid structure-related genes: molecular subgroups, immune infiltration, and prognostic implications in lung adenocarcinoma.多组学分析和三级淋巴结构相关基因的实验验证:肺腺癌的分子亚群、免疫浸润和预后意义。
Front Immunol. 2024 Sep 19;15:1453220. doi: 10.3389/fimmu.2024.1453220. eCollection 2024.
8
Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.三级淋巴结构可作为预测肝细胞胆管细胞癌的潜在预后生物标志物。
Hepatol Int. 2024 Aug;18(4):1310-1325. doi: 10.1007/s12072-024-10694-2. Epub 2024 May 20.
9
The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer.三级淋巴结构对非小细胞肺癌肿瘤预后和免疫微环境的影响。
Sci Rep. 2024 Jul 15;14(1):16246. doi: 10.1038/s41598-024-64980-y.
10
Immature central tumor tertiary lymphoid structures are associated with better prognosis in non-small cell lung cancer.不成熟的中央肿瘤三级淋巴结构与非小细胞肺癌的预后较好相关。
BMC Pulm Med. 2024 Mar 26;24(1):155. doi: 10.1186/s12890-024-02970-6.

引用本文的文献

1
Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer.非小细胞肺癌围手术期免疫检查点抑制剂免疫生物标志物的机制性见解
Transl Lung Cancer Res. 2025 Jul 31;14(7):2821-2841. doi: 10.21037/tlcr-2025-162. Epub 2025 Jul 16.
2
Tumor-infiltrating lymphocytes in NSCLC: from immune surveillance to immunotherapy.非小细胞肺癌中的肿瘤浸润淋巴细胞:从免疫监视到免疫治疗
Front Immunol. 2025 Jul 25;16:1610998. doi: 10.3389/fimmu.2025.1610998. eCollection 2025.
3
Spatial omics technology potentially promotes the progress of tumor immunotherapy.

本文引用的文献

1
Long-term retention of antigens in germinal centers is controlled by the spatial organization of the follicular dendritic cell network.生发中心中抗原的长期保留受滤泡树突状细胞网络的空间结构控制。
Nat Immunol. 2023 Aug;24(8):1281-1294. doi: 10.1038/s41590-023-01559-1. Epub 2023 Jul 13.
2
Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities.肿瘤相关巨噬细胞的动态极化及其在炎症肿瘤微环境中与肿瘤内 T 细胞的相互作用:从机制见解到治疗机会。
Front Immunol. 2023 May 12;14:1160340. doi: 10.3389/fimmu.2023.1160340. eCollection 2023.
3
空间组学技术有可能推动肿瘤免疫治疗的进展。
Br J Cancer. 2025 Jun 2. doi: 10.1038/s41416-025-03075-5.
Deciphering the maturation of tertiary lymphoid structures in cancer and inflammatory diseases of the digestive tract using imaging mass cytometry.
利用成像质谱细胞术解析癌症和消化道炎症性疾病中三级淋巴结构的成熟过程。
Front Immunol. 2023 Apr 18;14:1147480. doi: 10.3389/fimmu.2023.1147480. eCollection 2023.
4
Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.肿瘤内三级淋巴结构 (TLS) 的成熟受肺癌引流淋巴结的影响。
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-005539.
5
Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.食管鳞状细胞癌中肿瘤周围三级淋巴结构的密度和成熟度可预测患者的生存和对免疫检查点抑制剂的反应。
Br J Cancer. 2023 Jun;128(12):2175-2185. doi: 10.1038/s41416-023-02235-9. Epub 2023 Apr 4.
6
Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.Ⅰ期肺腺癌中三级淋巴结构的临床意义及分子特征。
Cancer Med. 2023 Apr;12(8):9547-9558. doi: 10.1002/cam4.5731. Epub 2023 Mar 6.
7
Follicle-like tertiary lymphoid structures: A potential biomarker for prognosis and immunotherapy response in patients with laryngeal squamous cell carcinoma.滤泡样三级淋巴结构:喉鳞状细胞癌患者预后和免疫治疗反应的潜在生物标志物。
Front Immunol. 2023 Jan 27;14:1096220. doi: 10.3389/fimmu.2023.1096220. eCollection 2023.
8
Tertiary lymphoid structures in lung adenocarcinoma: characteristics and related factors.肺腺癌中的三级淋巴结构:特征及相关因素。
Cancer Med. 2022 Aug;11(15):2969-2977. doi: 10.1002/cam4.4796. Epub 2022 Jul 8.
9
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.伴三级淋巴结构的软组织肉瘤中的帕博利珠单抗:PEMBROSARC 试验队列的 2 期研究
Nat Med. 2022 Jun;28(6):1199-1206. doi: 10.1038/s41591-022-01821-3. Epub 2022 May 26.
10
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.B 细胞和三级淋巴结构作为肿瘤免疫微环境和临床结局的决定因素。
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457. doi: 10.1038/s41571-022-00619-z. Epub 2022 Apr 1.